Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38- population survives chemotherapy and is most probable the cause of minimal residual disease (MRD). The outgrowth of MRD causes relapse and MRD can therefore serve as a prognostic marker. The key role of leukemogenic CD34+CD38- cells led us to investigate whether they can be detected under MRD conditions. Various markers were identified to be aberrantly expressed on the CD34+CD38- population in AML and high-risk MDS samples at diagnosis, including C-type lectin-like molecule-1 and several lineage markers/marker-combinations. Fluorescent in situ hybridization analysis revealed that marker-positive cells were indeed of malignant origin. The markers were neither expressed on normal CD34+CD38- cells in steady-state bone marrow (BM) nor in BM after chemotherapy. We found that these markers were indeed expressed in part of the patients on malignant CD34+CD38- cells in complete remission, indicating the presence of malignant CD34+CD38- cells. Thus, by identifying residual malignant CD34+CD38- cells after chemotherapy, MRD detection at the stem cell level turned out to be possible. This might facilitate characterization of these chemotherapy-resistant leukemogenic cells, thereby being of help to identify new targets for therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AML leukemia initiating cells frequently have surface-phenotype features of lineage-commitment (CD34+38+, CLL-1+, CD71+, CD90−, c-Kit-)(42–52).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [46]
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Cozzio, A., Passegué, E., Ayton, P. M., Karsunky, H., Cleary, M. L., & Weissman, I. L. (2003) · Genes & Development · doi:10.1101/gad.1143403 · Cited by 663
van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0468 · Cited by 375 · cited 1×
“We recently described that C-type lectin-like molecule-1 (CLL-1) is present on AML CD34þCD38 cells in the majority of patients and absent on CD34þCD38 cells in normal BM (NBM), which makes it a suitable stem cell marker (van Rhenen et al., Blood (2005) 106, 6a abstract).”
BackgroundSelf-citationSan Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
Wulf, G. G., Wang, R.-Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M., & Goodell, M. A. (2001) · Blood · doi:10.1182/blood.v98.4.1166 · Cited by 326
Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3948 · Cited by 275
Cited by
Items 101–193 of 193
Verhagen, H. J. M. P., van Gils, N., Martiáñez, T., van Rhenen, A., Rutten, A. P., Denkers, F., de Leeuw, D. C., Smit, M. A., Tsui, M.-L., Klootwijk, L. L. E. D. V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.062 · Cited by 20
Self-citationNovel monoclonal antibody-based therapies for acute myeloid leukemia
Morsink, L. M., & Walter, R. B. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.002 · Cited by 19
Wang, J., Wang, W., Chen, H. H., Li, W., Huang, T., Zhang, W., Ling, W., Lai, P., Wang, Y., Geng, S., et al. (2021) · BioMed Research International · doi:10.1155/2021/6643948 · Cited by 18
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll, P. S., Yoshizato, T., Hellström‐Lindberg, E., Fioretos, T., Ebert, B. L., & Jacobsen, S. E. W. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13535 · Cited by 16
Diagnostic Potential of CD34+ Cell Antigen Expression in Myelodysplastic Syndromes
Smet, D. D., Trullemans, F., Jochmans, K., Renmans, W., Smet, L., Heylen, O., Bael, A.-M., Schots, R., Leus, B., & Waele, M. D. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpagvo27rptotv · Cited by 18
Hansen, Q., Bachas, C., Smit, L., & Cloos, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.140 · Cited by 25
OCT4 pseudogenes present in human leukemia cells
Guo, X., & Tang, Y. (2011) · Clinical and Experimental Medicine · doi:10.1007/s10238-011-0163-4 · Cited by 17
“This allows us to speculate that early markers indicating the early development of leukemia may confer poorer prognosis [28, 29].”
BackgroundMoshaver, B., Wouters, R., Kelder, A., Ossenkoppele, G. J., Westra, G. A. H., Kwidama, Z. J., Rutten, A. P., Kaspers, G. J. L., Zweegman, S., Cloos, J. J., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.04.004 · Cited by 18
Self-citationYu, Z., Liu, L., Shu, Q., Li, D., & Wang, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10767 · Cited by 17
Canali, A., Vergnolle, I., Bertoli, S., Largeaud, L., Nicolau-Travers, M.-L., Rieu, J., Tavitian, S., Huguet, F., Picard, M., Bories, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2237 · Cited by 18
Depreter, B., Weening, K., Vandepoele, K., Essand, M., Moerloose, B. D., Themeli, M., Cloos, J. J., Hanekamp, D., Moors, I., D’hont, I., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222612 · Cited by 18
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia
Venugopal, S., Daver, N. G., & Ravandi, F. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00612-w · Cited by 17
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 17
“Similarly, PR1-specific CTLs identified in the blood of AML patients have shown the capability to eliminate leukemic blasts in vitro and reduce tumor burden in xenograft models [281, 282].”
Bhattacharjee, R., Ghosh, S., Nath, A., Basu, A., Biswas, O., Patil, C. R., & Kundu, C. N. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103753 · Cited by 18
The mythological chimera and new era of relapse prediction post-transplant
Ciurea, S. O., Kothari, A., Sana, S., & Malki, M. M. A. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100997 · Cited by 15
Pleșa, A., Elhamri, M., Clapisson, G., Mattei, E., Gazzo, S., Héquet, O., Tigaud, I., Michallet, M., Dumontet, C., & Thomas, X. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.927453 · Cited by 14
Horne, G. A., & Copland, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1303477 · Cited by 15
Bill, M., Aggerholm, A., Kjeldsen, E., Roug, A. S., Hokland, P., & Nederby, L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15711 · Cited by 17
“…receptor, a relevant marker of leukaemic blasts (Larsen et al, 2012; Roug et al, 2014), has been proposed as a specific marker of LSCs in AML (van Rhenen et al, 2007a; Terwijn et al, 2014), as the CLEC12A protein is not expressed on normal CD34+CD38 cells, but aberrant expression on this…”
BackgroundMethodInfluentialGianfaldoni, G., Mannelli, F., Intermesoli, T., Bencini, S., Giupponi, D., Farina, G., Cutini, I., Bonetti, M. I., Masciulli, A., Audisio, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000406 · Cited by 15
The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View
Mosna, F. (2024) · Cancers · doi:10.3390/cancers16132359 · Cited by 15
Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age
Roug, A. S., Hansen, M. H., Nederby, L., & Hokland, P. (2014) · British Journal of Haematology · doi:10.1111/bjh.13048 · Cited by 13
Hybel, T. E., Jensen, S. H., Rodrigues, M. A., Hybel, T. E., Pedersen, M. N., Qvick, S. H., Enemark, M. H., Bill, M., Rosenberg, C. A., & Ludvigsen, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126465 · Cited by 14
“Thus far, all presented model performance metrics were based on pooled HSC and LSC data sets from multiple NBM and AML samples, respectively.”
BackgroundMethodHigher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer
Velcheti, V., Radivoyevitch, T., & Saunthararajah, Y. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174175 · Cited by 12
Can we finally target the leukemic stem cells?
Jordan, C. T. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.006 · Cited by 12
“In the course of treatment, the population must be continuously monitored, as has been done successfully by Gerrit Jan Schuurhuis and colleagues.(14) The panel of antibodies must be customized for each patient because each patient may have a different leukemic stem cell phenotype.”
MethodHoang, V. T., Hoffmann, I., Borowski, K., Zepeda‐Moreno, A., Ran, D., Buss, E. C., Wuchter, P., Eckstein, V., & Ho, A. D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-508-8_19 · Cited by 11
Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges
Gaipa, G., Buracchi, C., & Biondi, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1504680 · Cited by 11
Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia
Perna, F., Espinoza-Gutarra, M. R., Bombaci, G., Farag, S. S., & Schwartz, J. E. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_8 · Cited by 12
Mizuta, S., Iwasaki, M., Bandai, N., Yoshida, S., Watanabe, A., Takashima, H., Ueshimo, T., Bandai, K., Fujiwara, K., Hiranuma, N., et al. (2023) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22148 · Cited by 9
Carlson, K.-S., & Guzmán, M. L. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0157-2 · Cited by 10
Leukemia stem cell immunophenotyping tool for diagnostic, prognosis, and therapeutics
de Rezende, M. M., Ferreira, A. T., & Paredes‐Gamero, E. J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29394 · Cited by 10
“…and well described type of leukemia, yet new therapies are needed to cure it and to improve its survival rate (Blume et al., 2018; De Grandis et al., 2017; Garg, Shanmukhaiah et al., 2016; Huang et al., 2015; Qiu et al., 2014; Quek et al., 2016; Wang et al., 2017; Yabushita et al., 2018).”
BackgroundMethodInfluentialDas, N., Panda, D., Gajendra, S., Gupta, R., Thakral, D., Kaur, G., Khan, A., Singh, V. K., Vemprala, A., Bakhshi, S., et al. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14250 · Cited by 10
“…as well as high yielding tactic than running multiple antibody tubes for the same sample as depicted by Zeijlemaker et al. 10 Van Rhenen et al. 19 and Terwijn et al. 24 demonstrated that CLL-1 is an excellent distinguishing marker for LSCs from normal stem cells, with stable expression…”
BackgroundWang, B., Yang, B., Wu, W., Liu, X., & Li, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08455-7 · Cited by 9
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
Martiáñez, T., de Leeuw, D. C., Vermue, E., Ossenkoppele, G. J., & Smit, L. (2017) · Cancers · doi:10.3390/cancers9070074 · Cited by 9
Self-citationHuman myeloid inhibitory C‐lectin: a highly specific and stable acute myeloid leukemia marker
Eissa, D. S., Kandeel, E. Z., & Ghareeb, M. (2016) · Hematological Oncology · doi:10.1002/hon.2352 · Cited by 8
Li, S., Chen, M., Huang, X.-Y., Wang, H., & Chang, Y. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2285985 · Cited by 7
“Based on antigen expression such as Tim-3, CD123, and CLL-1 on CD34 + CD38 − cells of AML patients [58,60], LSCs could be identified and functionally confirmed ex vivo and in vivo [58,60,76].”
BackgroundThe concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target
Hokland, P., Woll, P. S., Hansen, M. H., & Bill, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16104 · Cited by 7
Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Zeijlemaker, W., & Schuurhuis, G. J. (2013) · InTech eBooks · doi:10.5772/52080 · Cited by 8
Self-citationPalmieri, R., Buccisano, F., Arena, V., Consalvo, M. A. I., Piciocchi, A., Maurillo, L., Principe, M. I. D., Veroli, A. D., Paterno, G., Conti, C., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2005042 · Cited by 6
Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry
Kusenda, J., FAJTOVA, M., & KOVARIKOVA, A. (2013) · Neoplasma · doi:10.4149/neo_2014_017 · Cited by 8
Heiblig, M., Elhamri, M., Thomas, X., Pleșa, A., Raffoux, E., & Hayette, S. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.017 · Cited by 6
Youssef, M. M., & Park, C. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1724473 · Cited by 7
Immunophenotypic features of leukemic stem cells and bulk of blasts in acute myeloid leukemia
Іванівська, Т. С., Sklyarenko, L. M., Zavelevich, M. P., Philchenkov, A. A., Koval, S. V., Polishchuk, A. S., & Df, G. (2019) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-41-no-3.13492 · Cited by 5
Zhang, L., Deeb, G., Deeb, K. K., Vale, C., Barclift, D. P., & Papadantonakis, N. (2024) · Cancers · doi:10.3390/cancers16081503 · Cited by 9
“Van Rhenen et al. showed that the CD34 CD38 population in AML and high-risk MDS samples at diagnosis is resistant to chemotherapy, and detection of this population using FACS assay can be used for monitoring the disease and characterization of chemotherapy-resistant neoplastic cells [119].”
MethodReprint of: Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Vyas, P., Appelbaum, F. R., & Craddock, C. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.032 · Cited by 6
Appelbaum, J., Pinto, N. R., & Orentas, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00011-1 · Cited by 6
Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia
Barneh, F., Koedijk, J. B., Wijnen, N. E., Meulendijks, T., Ashtiani, M., Dünnebach, E., Dautzenberg, N. M. M., Cornel, A. M., Krippner‐Heidenreich, A., Klein, K., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285707 · Cited by 4
Gao, Q., Chan, A. C. L., Zhang, J., Sun, X., Burke, A., Miu, O., Nguyen, N., Zhang, S. J., Reminick, J., Wardrope, J., et al. (2025) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22233 · Cited by 7
“…with a “ different from normal ” (DfN) strategy which requires a thorough understanding of developmental immunophenotypes (Aanei et al., 2021; Cremers et al., 2015; Kern et al., 2013; Lucas & Hergott, 2023; Ouyang et al., 2015; van Rhenen et al., 2007; Wang et al., 2023; Wood, 2016; Wood, 2020).”
Wei, Y., Zheng, H., Lockyer, P. P., Darbaniyan, F., Li, Z., Kanagal‐Shamanna, R., Soltysiak, K. A., Yang, H., Gañán‐Gómez, I., Bravo, G. M., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2116932 · Cited by 5
Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia
Ramdas, B., Dayal, N., Pandey, R., Larocque, E. A., Kanumuri, R., Pasupuleti, S. K., Liu, S., Kanellopoulou, C., Chu, E. F. Y., Mohallem, R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169245 · Cited by 4
Daver, N. G., Blachly, J. S., Ghobadi, A., Advani, A. S., Muffly, L. S., Garciaz, S., Récher, C., Kahali, B., Sun, J., Jung, A. S., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3745 · Cited by 3
“CLL-1 is expressed in 70% to 87% of CD34+CD38 � AML blasts and is also present on CD34+CD38 � leukemic stem cells, which can be difficult to target because of their ability to acquire qui-escence and confer chemotherapy resistance, possibly resulting in relapse (43–46).”
Tao, Q., Zhang, Q., Wang, H., Xiao, H., Zhou, M., Liu, L., Qin, H., Wang, J., An, F., Zhai, Z., et al. (2021) · Biocell · doi:10.32604/biocell.2021.014139 · Cited by 3
Critical Updates to the Leukemia Stem Cell Model
Saunthararajah, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00004-8 · Cited by 3
Wang, B., Hua, X., Zhang, J., Gu, W., & Li, H. (2023) · Cancer Medicine · doi:10.1002/cam4.5704 · Cited by 3
Diagnosis of Acute Myeloid Leukaemia
Bacârea, A. (2012) · InTech eBooks · doi:10.5772/26177 · Cited by 3
Dutta, S., & Saxena, R. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-013-0317-5 · Cited by 3
Qadir, M., & JAMY, O. H. (2026) · Medical Sciences · doi:10.3390/medsci14010123 · Cited by 2
“Including LSC-directed panels improves sensitivity, lowers false-negative rates, and exhibits a robust association with the likelihood of recurrence, even in the post-transplant context [41].”
Place de la cytométrie en flux dans le diagnostic et le suivi des leucémies aiguës
Béné, M. C., & Lacombe, F. (2015) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(15)30072-1 · Cited by 6
Bedair, H. M., Attia, M. H., Gohar, S. F., Khalaf, F. M., El-Din, S. B., & Rabie, H. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00183-8 · Cited by 2
Stolpa, W., Mizia-Malarz, A. J., Zapała, M., & Zwiernik, B. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1213009 · Cited by 2
Clec12a is required for the pathogenesis of NUP98::NSD1 AML
Mohanty, S., Cano, F. C., Gabdoulline, R. R., Lai, C. K., Othman, B., Sudarsanam, H., Eder, T., Grebien, F., Lipka, D. B., Henschler, R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015739 · Cited by 2
Khan, A., Gajendra, S., Singh, V. K., Thakral, D., Bakhshi, S., Sahoo, R. K., Seth, R., Rai, S., & Gupta, R. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108170 · Cited by 1
Immunopathology and Immunotherapy of Myeloid Leukemia
Snauwaert, S., Vandekerckhove, B., & Kerre, T. C. C. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_5 · Cited by 1
Attia, F. M., Amani.A.El, B., Mohamed, A. A. N., Amany, M. H., Abdel, A. M. M., & Magdy, A. E. B. (2014) · International Journal of Medicine and Medical Sciences · doi:10.5897/ijmms2009.394 · Cited by 1
Value of human CLEC12A expression in acute myeloid leukemia
Hamed, G., & Fattah, M. A. (2016) · The Egyptian Journal of Haematology · doi:10.4103/1110-1067.198648 · Cited by 1
Recent advances in immunotherapy of acute leukemia via chimeric antigen receptor-engineered T cells
Min, W. A. N. G., Wang, J. X., & Xu, Y. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00266 · Cited by 1
Identification of cooperating genetic events in acute leukemia
Liu, T. (2009) · edoc (University of Basel) · doi:10.5451/unibas-004872254 · Cited by 1
Targeting acute myelogenous leukemia stem cells
Guzmán, M. L., Schuurhuis, G. J., & Jordan, C. T. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511605536.007
Self-citationStem‐cell Biology in Normal and Malignant Hematopoiesis
Zeidan, A. M., & Wetzler, M. (2010) · Wiley eBooks · doi:10.1002/9781444327359.ch1
Characterization of relapsed Acute Myeloid Leukemia
Bachas, C. (2014) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Shen, Y., Liu, Q., Luo, Y., Zhang, P., Fengxia, B., Cheng, S., & Lou, S. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2146-5
Targeting of AML-Leukemic Stem Cells with Monoclonal Antibodies
Lee, E. M., & Lock, R. B. (2009) · Future Oncology · doi:10.2217/fon.09.115
Direktor, Ä., & Handgretinger, R. (2010)
Gorczyca, W., & Emmons, F. N. (2008) · CRC Press eBooks · doi:10.3109/9781439806487-14
The molecular basis of acute myeloid leukemia
Rice, K. L., Buzzai, M., Altman, J. K., & Licht, J. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.070
Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33+disease?
Boddu, P. C., & Ravandi, F. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.21
An agonist antibody prefers relapsed AML for induction of cells that kill each other
Yea, K., Jones, T. M., Jung, D., Shin, S., Arlian, B. M., Han, K. H., Zha, Z., Kim, M. S., Oh, Y., Zhang, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40087-7
Deb, D. (2019) · Helda - University of Helsinki Institutional Repository
OCT4 pseudogenes present in human leukemia cells
Tang, X. G. (2012)
Diagnosis of Acute Myeloid Leukaemia
Bacârea, A. (2014)
Three essays on licensing university inventions
Munteanu, R. (2007) · eScholarship (California Digital Library)
Immunopathology and Immunotherapy of Myeloid Leukemia
Snauwaert, S., Rahmani, F., Vandekerckhove, B., & Kerre, T. C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_4
Differential diagnosis – chromosomal/molecular changes
Gorczyca, W., & Emmons, F. N. (2008) · CRC Press eBooks · doi:10.3109/9781439806487-16
Christopeit, M., Tischer, J., Bornhäuser, M., Uharek, L., Pfrepper, C., Behre, G., Niederwieser, D. W., Kroger, N., Rösler, W., Klein, S., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-014-2297-4
EXPRESSION PROFILE OF SOME MARKERS OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA
Shlapatska, L. M., Polishchuk, A. S., & Df, G. (2023) · Oncology · doi:10.15407/oncology.2023.03.180
Heo, S.-K., Noh, E.-K., Ju, L. J., Sung, J. Y., Jeong, Y. K., Cheon, J., Koh, S. J., Min, Y. J., Choi, Y., & Jo, J.-C. (2020) · Figshare · doi:10.6084/m9.figshare.12097119
Heo, S.-K., Noh, E.-K., Ju, L. J., Sung, J. Y., Jeong, Y. K., Cheon, J., Koh, S. J., Min, Y. J., Choi, Y., & Jo, J.-C. (2020) · Figshare · doi:10.6084/m9.figshare.12097110
Heo, S.-K., Noh, E.-K., Ju, L. J., Sung, J. Y., Jeong, Y. K., Cheon, J., Koh, S. J., Min, Y. J., Choi, Y., & Jo, J.-C. (2020) · Figshare · doi:10.6084/m9.figshare.12097125
Heo, S.-K., Noh, E.-K., Ju, L. J., Sung, J. Y., Jeong, Y. K., Cheon, J., Koh, S. J., Min, Y. J., Choi, Y., & Jo, J.-C. (2020) · Figshare · doi:10.6084/m9.figshare.12097128
Doherty, E., & Heslop, H. E. (2026) · Advances in Oncology · doi:10.1016/j.yao.2026.01.005
Chuah, S., Li, M., Ang, K. S., Gascoigne, N. R. J., & Chen, J. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.20.739448
Exploring the Utility of ALDH1 as a Marker for the Cancer Stem Cell Population in OCCC Cell Lines
Gebreyes, B., Kolendowski, B., Ramos-Valdes, Y., Shepherd, T. G., & DiMattia, G. E. (2026) · Cells · doi:10.3390/cells15171509
“CSCs share several traits with normal stem cells and can be identified by a unique profile of cell surface and intracellular markers in both hematological and solid tumours [20–25].”
Recent Advances in Chronic Myeloid Leukaemia (CML): Emerging Molecular and Immunotherapeutic Targets
Dai, J., Zheng, P., Liu, J., Cheng, L., Zheng, X. W., Chen, L., Jiang, J., & Zheng, Z. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl48912
Metadata
- Authors
- van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Schuurhuis, G J
- Venue
- Leukemia
- Published
- 2007-05-24
- Volume
- 21
- Issue
- 8
- Pages
- 1700-1707
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2071293034
- Cited by
- 193
- References
- 20
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 12 · 2021: 9 · 2020: 12 · 2019: 16 · 2018: 14 · 2017: 17 · 2016: 9 · 2015: 9 · 2014: 15 · 2013: 15 · 2012: 8
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, leukemia stem cells, CD34+CD38- cells, minimal residual disease, complete remission, high-risk myelodysplastic syndrome, chemoresistance, prognostic factors, bone marrow-derived stem cells
- MeSH terms
- Acute Disease, Adolescent, Adult, Aged, Bone Marrow, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Leukemia, Myeloid, Male, Middle Aged, Prognosis, Remission Induction, Risk Factors, Biomarkers, Tumor, Neoplastic Stem Cells, Survival Rate, Immunophenotyping, In Situ Hybridization, Fluorescence, Neoplasm, Residual, Antigens, CD34, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.